Year : 2016  |  Volume : 1  |  Issue : 2  |  Page : 38-44

China expert consensus on clinical application of the drug-coated balloon

1 Department of Cardiology, Peoples Liberation Army General Hospital, Beijing, China
2 Department of Cardiology, Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China
3 Department of Cardiology, Second Affiliated Hospital of Jilin University, Changchun, China
4 Department of Cardiology, Beijing Hospital, Beijing, China
5 Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Henan, China
6 Department of Cardiology, Fuwai Cardiovascular Hospital, Beijing, China
7 Department of Cardiology, Guangdong General Hospital, Guangzhou, China
8 Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, China
9 Department of Cardiology, Henan Province People's Hospital, Zhengzhou, China
10 Department of Cardiology, Shanxi Cardiovascular Hospital, Shanxi, China
11 Department of Cardiology, People's Hospital of Liaoning Province, Shenyang, China
12 Department of Cardiology, Peking University First Hospital, Beijing, China
13 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

Correspondence Address:
Prof. Yundai Chen
The People's Liberation Army General Hospital, Beijing
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2470-7511.248364

Get Permissions

Percutaneous coronary intervention (PCI) has become the mainstay in the treatment of coronary heart disease (CHD). In the past 10 years, the number of PCI procedures for CHD has maintained an annual growth of 15%–20% on average in China. As a consequence, in-stent restenosis (ISR) has become an increasingly serious problem with the wide application of coronary stents. Certainly, current treatment regimens for ISR are unsatisfactory in some aspects. Coronary artery bypass surgery has many risk factors and contradictions and a second stent implantation is associated with the risk for recurrent ISR and additional stent implantations; the rate of recurrent ISR in lesions after plain old balloon angioplasty is high (up to 27%). Therefore, all these regimens are suboptimal for the treatment of ISR. In recent years, drug-coated balloon (DCB), a novel interventional technique, has been increasingly used in coronary and peripheral artery interventions in Europe and Asia. In China, several DCB products have been or will be marketed for clinical application. The introduction of DCB provides a new choice for the treatment of coronary artery diseases in China. Based on several national and international clinical trials, >20 experienced experts in the PCI field from China have proposed the China expert consensus on clinical application of the DCB with evidence-based validation and session discussion in order to promote the standardized application of the DCB in the treatment of coronary artery diseases in China.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded238    
    Comments [Add]    
    Cited by others 3    

Recommend this journal